Thrivent Financial for Lutherans Purchases 198,718 Shares of HealthEquity, Inc. (NASDAQ:HQY)

Thrivent Financial for Lutherans boosted its position in HealthEquity, Inc. (NASDAQ:HQY) by 924.2% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 220,220 shares of the company’s stock after buying an additional 198,718 shares during the quarter. Thrivent Financial for Lutherans owned approximately 0.25% of HealthEquity worth $18,983,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently bought and sold shares of HQY. Cape Investment Advisory Inc. acquired a new position in shares of HealthEquity during the 4th quarter worth about $27,000. Rise Advisors LLC bought a new stake in HealthEquity during the first quarter worth about $28,000. International Assets Investment Management LLC acquired a new position in HealthEquity during the second quarter valued at approximately $35,000. YHB Investment Advisors Inc. bought a new position in HealthEquity in the first quarter valued at approximately $40,000. Finally, Fidelis Capital Partners LLC acquired a new position in shares of HealthEquity during the 1st quarter worth approximately $42,000. Institutional investors own 99.55% of the company’s stock.

HealthEquity Stock Performance

Shares of NASDAQ:HQY opened at $78.80 on Wednesday. HealthEquity, Inc. has a 12-month low of $61.81 and a 12-month high of $88.26. The company’s 50 day moving average price is $76.16 and its two-hundred day moving average price is $79.29. The firm has a market cap of $6.86 billion, a PE ratio of 85.65, a PEG ratio of 1.19 and a beta of 0.52. The company has a quick ratio of 4.10, a current ratio of 4.10 and a debt-to-equity ratio of 0.51.

Insider Buying and Selling

In other HealthEquity news, Director Frank Corvino sold 7,705 shares of HealthEquity stock in a transaction on Monday, July 8th. The stock was sold at an average price of $81.89, for a total value of $630,962.45. Following the completion of the transaction, the director now directly owns 6,070 shares of the company’s stock, valued at approximately $497,072.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other HealthEquity news, Vice Chairman Stephen Neeleman sold 35,000 shares of the business’s stock in a transaction that occurred on Thursday, July 25th. The shares were sold at an average price of $79.86, for a total transaction of $2,795,100.00. Following the completion of the transaction, the insider now directly owns 89,769 shares in the company, valued at $7,168,952.34. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Frank Corvino sold 7,705 shares of the firm’s stock in a transaction on Monday, July 8th. The shares were sold at an average price of $81.89, for a total value of $630,962.45. Following the completion of the sale, the director now directly owns 6,070 shares in the company, valued at approximately $497,072.30. The disclosure for this sale can be found here. 2.20% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research firms recently weighed in on HQY. Robert W. Baird raised their target price on shares of HealthEquity from $98.00 to $104.00 and gave the company an “outperform” rating in a research note on Tuesday, June 4th. Deutsche Bank Aktiengesellschaft upped their price objective on HealthEquity from $102.00 to $103.00 and gave the company a “buy” rating in a research note on Wednesday, September 4th. Bank of America reduced their target price on HealthEquity from $105.00 to $100.00 and set a “buy” rating for the company in a research note on Wednesday, September 4th. KeyCorp increased their price target on HealthEquity from $95.00 to $100.00 and gave the company an “overweight” rating in a research note on Wednesday, June 5th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $105.00 price objective on shares of HealthEquity in a research report on Wednesday, September 4th. One investment analyst has rated the stock with a hold rating and twelve have given a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $103.83.

HealthEquity Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.